Table 2 Correlation between TOP2A expression and response to Pegylated Lyposomal Doxorubicin (PLD) in terms of time to progression (TTP)
From: TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers
Time To Progression (TTP) to PLD | TOP2A < 18% | TOP2A ≥ 18% | p-value |
|---|---|---|---|
All patients, months (CI 95%) | 4,5 (3,1-5,9) | 6,7 (4,8-8,6) | 0,085 |
TTP according to Platinum Free Interval | |||
 PR | 3,7 (2,6-4,9) | 4,9 (2,9-6,9) | 0,445 |
 PPS | 5,6 (2,7-8,6) | 9,1 (5,8-12,4) | 0,185 |
TTP according to chemoterapeutic regimen | |||
 PLD monotherapy | 3,4 (2,5-4,3) | 5,8 (3,7-3,9) | 0,035 |
 Carboplatin-PLD | 8,0 (3,5-12,4) | 9,6 (5,7-13,5) | 0,796 |
 PLD-Trabectidin | 1,8 (0,6-3,2) | 3,5 (0,6-6,3) | 0,358 |